Cerity Partners’s Janux Therapeutics JANX Stock Holding History

Cerity Partners’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,478	Closed	-$239K	–	2543
2024 Q4	$239K	Buy	+4,478	New	+$237K	﹤0.01%	2156
2024 Q2	–	Sell	-21,431	Closed	-$807K	–	2312
2024 Q1	$807K	Sell	21,431 -39,502	-65%	-$860K	﹤0.01%	1370
2023 Q4	$654K	Buy	+60,933	New	+$527K	﹤0.01%	1158
2023 Q3	–	Sell	-60,933	Closed	-$723K	–	1556
2023 Q2	$723K	Buy	+60,933	New	+$814K	﹤0.01%	1038
2022 Q4	–	Sell	-105,933	Closed	-$1.43M	–	1510
2022 Q3	$1.43M	Sell	105,933 -45,000	-30%	-$601K	0.02%	435
2022 Q2	$1.84M	Hold	150,933	–	–	0.02%	423
2022 Q1	$2.16M	Hold	150,933	–	–	0.03%	318
2021 Q4	$2.98M	Buy	+150,933	New	+$3.16M	0.05%	261

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Cerity Partners's JANX Position: Q1 2025 in Review

Cerity Partners sold out of Janux Therapeutics (JANX) in Q1 2025, closing a stake of 4,478 shares — an estimated $239K sold.

Cerity Partners first reported a position in JANX in Q4 2021 and held it in 8 quarters. The position peaked at $2.98M in Q4 2021. 181 funds tracked by Wall St. Rank hold JANX as of Q1 2025.

Cerity Partners reported no remaining Janux Therapeutics position as of Q1 2025 after selling out during the quarter.
Cerity Partners sold 4,478 Janux Therapeutics shares in Q1 2025, an estimated $239K.
Cerity Partners first reported a position in Janux Therapeutics in Q4 2021 and held it in 8 quarters.
Cerity Partners's Janux Therapeutics position peaked at $2.98M in Q4 2021.
181 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2025.

Based on Cerity Partners's 13F filing for Q1 2025, filed 30 Apr 2025.